Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research · Oct 9, 2026
Critical Review: Evogene (NASDAQ:EVGN) vs. Allarity Therapeutics (NASDAQ:ALLR)Defense World · Oct 5, 2026
Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head AnalysisDefense World · Oct 1, 2026
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical DevelopmentGlobeNewsWire · Sep 30, 2026
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line ResearchGlobeNewsWire · Sep 28, 2026
Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)Defense World · Sep 27, 2026Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.25 | -$0.21 | Beat |
| May 15, 2026 | -$0.22 | -$0.17 | Beat |
| Mar 31, 2026 | -$0.22 | -$0.19 | Beat |
| Nov 14, 2025 | -$0.23 | -$0.19 | Beat |
| Aug 15, 2025 | -$0.21 | -$0.15 | Beat |
| May 9, 2025 | – | -$0.25 |